Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Revenue of Samsung Biologics Co.,Ltd. (207940.KS)
Revenue in 2023 (TTM): $2.7 B
According to Samsung Biologics Co.,Ltd.'s latest financial reports the company's current revenue (TTM) is $2.7 B. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Samsung Biologics Co.,Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $2.7 B | $1.32 B | $1.24 B | $819.39 M | $627.49 M |
| 2022 | $2.2 B | $1.07 B | $1 B | $738.21 M | $583.87 M |
| 2021 | $1.15 B | $531.48 M | $541.88 M | $410.64 M | $287.95 M |
| 2020 | $852.16 M | $304.41 M | $315.44 M | $194.6 M | $176.3 M |
| 2019 | $513.29 M | $140.47 M | $229.36 M | $113.72 M | $148.45 M |
| 2018 | $392 M | $106.2 M | $300.47 M | $221.66 M | $163.96 M |
| 2017 | $339.93 M | $96.43 M | $13.69 M | $-84,862,840 | $-70,945,702 |
| 2016 | $215.55 M | $19.41 M | $-71,305,419 | $-168,929,307 | $-129,365,651 |
| 2015 | $66.78 M | $-17,197,638 | $3.18 B | $1.82 B | $1.39 B |
| 2014 | $76.93 M | $-14,427,059 | $-51,243,364 | $-72,932,962 | $-70,168,127 |